These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30770534)

  • 61. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Local antibody immune responses in influenza patients and persons vaccinated with seasonal, pre-pandemic, and pandemic live attenuated influenza vaccines].
    Donina SA; Petukhova GD; Koren'kov DA; Grigor'eva EP; Kuznetsova SA; Losev IV; Rudenko LG; Naĭkhin AN
    Vopr Virusol; 2013; 58(3):37-42. PubMed ID: 24006632
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
    Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
    Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
    [No Abstract]   [Full Text] [Related]  

  • 64. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge.
    Jegaskanda S; Luke C; Hickman HD; Sangster MY; Wieland-Alter WF; McBride JM; Yewdell JW; Wright PF; Treanor J; Rosenberger CM; Subbarao K
    J Infect Dis; 2016 Sep; 214(6):945-52. PubMed ID: 27354365
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
    Lillie PJ; Berthoud TK; Powell TJ; Lambe T; Mullarkey C; Spencer AJ; Hamill M; Peng Y; Blais ME; Duncan CJ; Sheehy SH; Havelock T; Faust SN; Williams RL; Gilbert A; Oxford J; Dong T; Hill AV; Gilbert SC
    Clin Infect Dis; 2012 Jul; 55(1):19-25. PubMed ID: 22441650
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vaccination against influenza in patients with systemic sclerosis.
    Litinsky I; Balbir A; Zisman D; Mandelboim M; Mendelson E; Feld J; Braun Y; Anouk M; Kaufman I; Paran D; Caspi D; Elkayam O
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S7-11. PubMed ID: 22409886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 69. Partial Protection Induced by 2011-2012 Influenza Vaccine Against Serologically Evidenced A(H3N2) Influenza Virus Infections in Elderly Institutionalized People.
    Camilloni B; Basileo M; Menculini G; Tozzi P; Iorio AM
    Adv Exp Med Biol; 2016; 897():45-53. PubMed ID: 26577530
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.
    Goodeve A; Potter CW; Clark A; Jennings R; Schild GC; Yetts R
    J Hyg (Lond); 1983 Feb; 90(1):107-15. PubMed ID: 6822725
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season.
    Puig-Barberà J; Guglieri-López B; Tortajada-Girbés M; López-Labrador FX; Carballido-Fernández M; Mollar-Maseres J; Schwarz-Chavarri G; Baselga-Moreno V; Mira-Iglesias A; Díez-Domingo J;
    Vaccine; 2017 Dec; 35(52):7331-7338. PubMed ID: 29128380
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.
    Johnson C; Hohenboken M; Poling T; Jaehnig P; Kanesa-Thasan N
    J Infect Dis; 2015 Jul; 212(1):72-80. PubMed ID: 25538277
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.
    Wilkinson TM; Li CK; Chui CS; Huang AK; Perkins M; Liebner JC; Lambkin-Williams R; Gilbert A; Oxford J; Nicholas B; Staples KJ; Dong T; Douek DC; McMichael AJ; Xu XN
    Nat Med; 2012 Jan; 18(2):274-80. PubMed ID: 22286307
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine.
    Keitel WA; Cate TR; Couch RB
    Am J Epidemiol; 1988 Feb; 127(2):353-64. PubMed ID: 3337087
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.
    Kissling E; Valenciano M; Buchholz U; Larrauri A; Cohen JM; Nunes B; Rogalska J; Pitigoi D; Paradowska-Stankiewicz I; Reuss A; Jiménez-Jorge S; Daviaud I; Guiomar R; O'Donnell J; Necula G; Głuchowska M; Moren A
    Euro Surveill; 2014 Feb; 19(6):. PubMed ID: 24556348
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain.
    Mendelman PM; Rappaport R; Cho I; Block S; Gruber W; August M; Dawson D; Cordova J; Kemble G; Mahmood K; Palladino G; Lee MS; Razmpour A; Stoddard J; Forrest BD
    Pediatr Infect Dis J; 2004 Nov; 23(11):1053-5. PubMed ID: 15545863
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge.
    Cate TR; Couch RB
    Infect Immun; 1982 Oct; 38(1):141-6. PubMed ID: 7141686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.
    Elliott STC; Keaton AA; Chu JD; Reed CC; Garman B; Patel A; Yan J; Broderick KE; Weiner DB
    Hum Gene Ther; 2018 Sep; 29(9):1044-1055. PubMed ID: 30062926
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine.
    Clements ML; Betts RF; Tierney EL; Murphy BR
    J Clin Microbiol; 1986 Jan; 23(1):73-6. PubMed ID: 3700611
    [TBL] [Abstract][Full Text] [Related]  

  • 80. M2-Deficient Single-Replication Influenza Vaccine-Induced Immune Responses Associated With Protection Against Human Challenge With Highly Drifted H3N2 Influenza Strain.
    Eiden J; Volckaert B; Rudenko O; Aitchison R; Herber R; Belshe R; Greenberg H; Coelingh K; Marshall D; Kawaoka Y; Neumann G; Bilsel P
    J Infect Dis; 2022 Aug; 226(1):83-90. PubMed ID: 34323977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.